<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928744</url>
  </required_header>
  <id_info>
    <org_study_id>2011/43</org_study_id>
    <secondary_id>2011-A00964-37</secondary_id>
    <nct_id>NCT02928744</nct_id>
  </id_info>
  <brief_title>Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea</brief_title>
  <acronym>OSCILLOREVERS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limitation of expiratory flows is considered as the main determiner of dynamic distension and
      dyspnoea in chronic obstructive pulmonary disease (COPD). The analysis of proximal and distal
      resistances should allow to better appreciate the functional impact.

      This study should also allow to specify the best parameters in respiratory functional
      explorations useful for the follow-up in COPD and to specify the relevance of functional
      indications other than the forced expiration volume at 1 second (FEV1) or the functional
      residual capacity (FRC) to estimate in a more relevant way the clinical improve with the
      increase of the therapeutic load (increase of posology, association of two bronchodilatators,
      addition of an anti-inflammatory drug, thus etc…) at already handled patients suffering from
      a persistent dyspnoea insufficiently relieved.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of obstruction reversibility</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COPD</intervention_name>
    <description>Plethysmography</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COPD</intervention_name>
    <description>Forced oscillations</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD with dyspnoea with Medical Research Council scale (MRC) &gt;1,

          -  No exacerbation for 6 weeks

          -  No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours
             before the respiratory evaluation and the test of reversibility.

          -  Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic
             long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples
             LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1
             hour the day of the visit

          -  Having given a written consent

        Exclusion Criteria:

          -  Patient Under 18

          -  Other respiratory illness

          -  Clinically significant left cardiac failure

          -  Obesity with BMI &gt; 35 kg / m2)

          -  Unable to perform respiratory evaluations

          -  Contraindication to the salbutamol or to the ipratropium bromide or to one of its
             components

          -  Pregnant or breast-feeding woman

          -  Unable to agree

          -  No social security scheme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Neveu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistance</keyword>
  <keyword>Forced oscillations</keyword>
  <keyword>Dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

